IN2014KN01075A - - Google Patents

Info

Publication number
IN2014KN01075A
IN2014KN01075A IN1075KON2014A IN2014KN01075A IN 2014KN01075 A IN2014KN01075 A IN 2014KN01075A IN 1075KON2014 A IN1075KON2014 A IN 1075KON2014A IN 2014KN01075 A IN2014KN01075 A IN 2014KN01075A
Authority
IN
India
Prior art keywords
compounds
muscarinic
receptor
16this
agonists
Prior art date
Application number
Inventor
Miles Congreve
Giles Brown
Julie Cansfield
Benjamin Tehan
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of IN2014KN01075A publication Critical patent/IN2014KN01075A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

16This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I where n is 1 or 2; p is 0 1 or 2; q is 0 1 or 2; and R R are as defined herein.
IN1075KON2014 2011-11-18 2012-11-16 IN2014KN01075A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161632813P 2011-11-18 2011-11-18
PCT/GB2012/052857 WO2013072705A1 (en) 2011-11-18 2012-11-16 Muscarinic m1 receptor agonists

Publications (1)

Publication Number Publication Date
IN2014KN01075A true IN2014KN01075A (en) 2015-10-09

Family

ID=47278335

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1075KON2014 IN2014KN01075A (en) 2011-11-18 2012-11-16

Country Status (17)

Country Link
US (6) US9187451B2 (en)
EP (1) EP2780015B1 (en)
JP (2) JP6083818B2 (en)
CN (2) CN104039321B (en)
AU (3) AU2012338581B2 (en)
BR (1) BR112014012056B1 (en)
CA (1) CA2856076C (en)
DK (1) DK2780015T3 (en)
ES (1) ES2619829T3 (en)
GB (1) GB2511685A (en)
HK (1) HK1201737A1 (en)
HU (1) HUE033114T2 (en)
IN (1) IN2014KN01075A (en)
PL (1) PL2780015T3 (en)
PT (1) PT2780015T (en)
SG (1) SG11201402405QA (en)
WO (1) WO2013072705A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033114T2 (en) * 2011-11-18 2017-11-28 Heptares Therapeutics Ltd Muscarinic m1 receptor agonists
CN104640851B (en) 2012-09-18 2017-05-31 赫普泰雅治疗有限公司 As the bicyclic azepine compound of the M1 receptor stimulating agents of muscarine
GB2519470A (en) * 2013-09-18 2015-04-22 Heptares Therapeutics Ltd Bicyclic aza compounds as muscarinic M1 receptor agonists
NZ723103A (en) 2014-02-06 2022-09-30 Heptares Therapeutics Ltd Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201504675D0 (en) * 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) * 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
CN108226319A (en) * 2016-12-22 2018-06-29 亚宝药业集团股份有限公司 A kind of method for detecting optical isomer in Rivastigmine patch
TW201922758A (en) 2017-10-24 2019-06-16 美商歐樂根公司 Enamines and diastereo-selective reduction of enamines
JP6691928B2 (en) * 2018-02-07 2020-05-13 株式会社ジンズホールディングス Eyewear set and signal processing unit
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
CN113121495A (en) * 2020-01-10 2021-07-16 深圳市九明药业有限公司 Preparation method of desloratadine

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56110674A (en) 1980-01-24 1981-09-01 Janssen Pharmaceutica Nv Novel 11*cyclohexyl**44aryll44piperidine carboxylic acid derivative
US4369184A (en) 1980-01-24 1983-01-18 Janssen Pharmaceutica N.V. 1-(Cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
GB9300194D0 (en) 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
WO1996013262A1 (en) 1994-10-27 1996-05-09 Merck & Co., Inc. Muscarine antagonists
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
AU7478496A (en) 1995-10-31 1997-05-22 Merck & Co., Inc. Muscarine antagonists
US5854245A (en) * 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
DE69734774D1 (en) 1996-08-26 2006-01-05 Pfizer SPIROCYCLIC DOPAMINE RECEPTOR SUBTYPE LIGANDS
WO1998057641A1 (en) 1997-06-18 1998-12-23 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
GB9715892D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
AU2307999A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO1999032479A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparation and their use as muscarinic receptor (ant-)agonists
WO1999032486A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO1999032489A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
CZ286152B6 (en) 1998-03-13 2000-01-12 Miroslav Ing. Csc. Vlček Transparent and semitransparent diffraction elements, particularly holograms and process of their production
CN1118452C (en) * 1998-04-28 2003-08-20 大日本制药株式会社 1-[(1-substituted-4-piperidinyl) methyl]-4-piperidine derivatives, process for producing the same medicinal compositions containing the same and intermediate of these compounds
PL203117B1 (en) 1999-05-04 2009-08-31 Schering Corp Piperidine derivatives useful as ccr5 antagonists
CA2365900A1 (en) 1999-05-04 2000-11-09 Schering Corporation Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
US6387930B1 (en) 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
HUP0302380A2 (en) 1999-09-13 2004-03-01 Boehringer Ingelheim Pharmaceuticals, Inc. Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases, process for their preparation and pharmaceutical compositions containing them
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
CA2387535A1 (en) 1999-10-13 2001-04-19 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
AU2001297648A1 (en) * 2000-11-28 2002-08-28 Eli Lilly And Company Substituted carboxamides as inhibitors of factor xa
CA2444595A1 (en) 2001-04-20 2002-10-31 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
US7067507B2 (en) 2001-06-12 2006-06-27 Pharmacia & Upjohn Company Macrocycles useful in the treatment of Alzheimer's disease
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
GB0128378D0 (en) 2001-11-27 2002-01-16 Smithkline Beecham Plc Novel Compounds
CN100402032C (en) 2001-12-28 2008-07-16 阿卡蒂亚药品公司 Tetrahydroquinoline analogues as muscarinic agonists
US7550459B2 (en) 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
US20040171614A1 (en) 2002-02-06 2004-09-02 Schering-Plough Corporation Novel gamma secretase inhibitors
US7256186B2 (en) 2002-02-06 2007-08-14 Schering Corporation Gamma secretase inhibitors
MXPA04009477A (en) * 2002-03-28 2005-01-25 Jun Murakami Benzofuran derivative.
US7524852B2 (en) 2002-06-07 2009-04-28 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
WO2004014853A1 (en) 2002-07-31 2004-02-19 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
RU2323218C2 (en) 2002-09-30 2008-04-27 НьюроСёрч А/С Novel derivatives of 1,4-diazabicycloalkane and pharmaceutical composition based on thereof
CA2514473C (en) 2002-11-22 2008-05-27 Japan Tobacco Inc. Fused bicyclic nitrogen-containing heterocycles
KR100895968B1 (en) 2002-11-27 2009-05-07 인사이트 코포레이션 3-Aminopyrrolidine derivatives as modulators of chemokine receptors
JPWO2004069828A1 (en) 2003-02-04 2006-05-25 三菱ウェルファーマ株式会社 Piperidine compounds and their pharmaceutical uses
MXPA06000441A (en) 2003-07-17 2006-04-05 Astellas Pharma Inc 2-acylaminothiazole derivative or salt thereof.
US20070078120A1 (en) 2003-10-21 2007-04-05 Hitoshi Ban Novel piperidine derivative
WO2005077369A1 (en) 2004-02-05 2005-08-25 Schering Corporation Piperidine derivatives useful as ccr3 antagonists
CA2554671A1 (en) 2004-02-10 2005-08-18 F.Hoffmann-La Roche Ag Chemokine ccr5 receptor modulators
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
US7504424B2 (en) 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
JP2008521821A (en) 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド Muscarinic receptor modulators
JP4774995B2 (en) * 2005-01-12 2011-09-21 アステラス製薬株式会社 Pharmaceutical composition comprising an acylaminothiazole derivative as an active ingredient
EP1863490A2 (en) 2005-03-28 2007-12-12 Vertex Pharmaceuticals Incorporated Muscarinic modulators
EP2468743A1 (en) 2005-06-24 2012-06-27 Toyama Chemical Co., Ltd. Nitrogen-containing bicyclic compounds useful as antibacterial agents
US7858635B2 (en) 2005-12-22 2010-12-28 Vertex Pharmaceuticals Incorporated Spiro compounds as modulators of muscarinic receptors
CN101389630A (en) 2005-12-29 2009-03-18 艾博特公司 Protein kinase inhibitors
WO2007100670A1 (en) 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Spiro condensed piperidnes as modulators of muscarinic receptors
AU2007221214A1 (en) 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
US7696201B2 (en) 2006-08-15 2010-04-13 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
BRPI0718874A2 (en) 2006-12-22 2015-06-23 Novartis Ag Organic compounds
WO2008117229A1 (en) 2007-03-23 2008-10-02 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US8119661B2 (en) 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
US20090221567A1 (en) * 2008-02-28 2009-09-03 Astrazeneca Ab Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof 177
JP5564033B2 (en) 2008-03-27 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Aza-bicyclohexyl substituted indolylalkylamino derivatives as novel inhibitors of histone deacetylase
EP2344457A1 (en) 2008-10-29 2011-07-20 Grünenthal GmbH Substituted spiroamines
PE20120061A1 (en) * 2008-12-19 2012-02-19 Boehringer Ingelheim Int PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE CCR2 RECEPTOR
JP5675773B2 (en) 2009-04-17 2015-02-25 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ 4-Azetidinyl-1-phenyl-cyclohexane antagonist of CCR2
FR2945531A1 (en) 2009-05-12 2010-11-19 Sanofi Aventis 7-AZA-SPIRO® 3,5-NONANE-7-CARBOXYLATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2011112825A2 (en) 2010-03-10 2011-09-15 Vanderbilt University Heterocyclyl-azabicyclo[3.2.1]octane analogs as selective m1 agonists and methods of making and using same
WO2011133750A1 (en) 2010-04-22 2011-10-27 Janssen Pharmaceutica Nv Indazole compounds useful as ketohexokinase inhibitors
EP2563127A4 (en) 2010-04-27 2013-11-06 Merck Sharp & Dohme Prolylcarboxypeptidase inhibitors
WO2011143057A1 (en) 2010-05-11 2011-11-17 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
WO2011150183A1 (en) 2010-05-28 2011-12-01 Ge Healthcare Limited Radiolabeled compounds and methods thereof
MX2013003034A (en) 2010-09-17 2013-08-15 Array Biopharma Inc Piperidinyl-substituted lactams as gpr119 modulators.
WO2012125661A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Substituted 3-azabicyclo[3.1.0]hexane derivatives useful as ccr2 antagonists
JP2013010719A (en) 2011-06-30 2013-01-17 Dainippon Sumitomo Pharma Co Ltd Benzimidazolone and oxindole derivative, and pharmaceutical application of them
HUE033114T2 (en) 2011-11-18 2017-11-28 Heptares Therapeutics Ltd Muscarinic m1 receptor agonists
CN104640851B (en) 2012-09-18 2017-05-31 赫普泰雅治疗有限公司 As the bicyclic azepine compound of the M1 receptor stimulating agents of muscarine
US9593106B2 (en) 2013-02-07 2017-03-14 Heptares Therapeutics Limited Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
NZ723103A (en) 2014-02-06 2022-09-30 Heptares Therapeutics Ltd Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
MA41633B1 (en) 2015-02-13 2019-07-31 Suven Life Sciences Ltd Amide Compounds as 5-HT4 Receptor Agonists
GB201504675D0 (en) 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513740D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
US10259787B2 (en) 2016-10-14 2019-04-16 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
GB201709652D0 (en) 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
TW201922758A (en) 2017-10-24 2019-06-16 美商歐樂根公司 Enamines and diastereo-selective reduction of enamines
GB201810245D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202103211D0 (en) 2021-03-08 2021-04-21 Heptares Therapeutics Ltd Pharmaceutical compounds for use in therapy

Also Published As

Publication number Publication date
US20180153900A1 (en) 2018-06-07
GB201410398D0 (en) 2014-07-23
US11793817B2 (en) 2023-10-24
US9907805B2 (en) 2018-03-06
EP2780015B1 (en) 2017-01-04
CN104039321B (en) 2017-02-22
US20210353637A1 (en) 2021-11-18
HK1201737A1 (en) 2015-09-11
AU2017201505B2 (en) 2018-10-25
US9187451B2 (en) 2015-11-17
CN106831541B (en) 2019-09-06
BR112014012056A8 (en) 2017-06-20
US20140329803A1 (en) 2014-11-06
BR112014012056B1 (en) 2021-12-14
AU2018236871B2 (en) 2020-02-27
JP2017095501A (en) 2017-06-01
US20170157139A1 (en) 2017-06-08
DK2780015T3 (en) 2017-03-27
WO2013072705A1 (en) 2013-05-23
JP6404374B2 (en) 2018-10-10
ES2619829T3 (en) 2017-06-27
AU2012338581A1 (en) 2014-06-05
US20160068508A1 (en) 2016-03-10
US10413553B2 (en) 2019-09-17
AU2012338581B2 (en) 2016-12-08
EP2780015A1 (en) 2014-09-24
AU2017201505A1 (en) 2017-03-23
US9573929B2 (en) 2017-02-21
HUE033114T2 (en) 2017-11-28
PL2780015T3 (en) 2017-06-30
GB2511685A (en) 2014-09-10
JP2015501799A (en) 2015-01-19
CA2856076A1 (en) 2013-05-23
CA2856076C (en) 2020-02-25
US10973832B2 (en) 2021-04-13
PT2780015T (en) 2017-03-23
JP6083818B2 (en) 2017-02-22
BR112014012056A2 (en) 2020-10-27
AU2018236871A1 (en) 2018-10-18
CN104039321A (en) 2014-09-10
US20200253982A1 (en) 2020-08-13
SG11201402405QA (en) 2014-09-26
CN106831541A (en) 2017-06-13

Similar Documents

Publication Publication Date Title
IN2014KN01075A (en)
CA2883210C (en) Bicyclic aza compounds as muscarinic m1 receptor agonists
MX2020010674A (en) Muscarinic receptor agonists.
MX2013004329A (en) Substituted 6-amino-nicotinamides as kcnq2/3 modulators.
MD20150035A2 (en) Bruton's tyrosine kinase inhibitors
EP2582676A4 (en) Tetrahydroquinoline amide m1 receptor positive allosteric modulators
MX2020010535A (en) Methods of treating cancer.
MX2020001236A (en) Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists.
MX344530B (en) Substituted benzene compounds.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
UA115558C2 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
IN2014MN00988A (en)
IN2015DN01119A (en)
MY160075A (en) Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
IN2014CN02273A (en)
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2014000964A (en) Substituted heterocyclic aza derivatives.
IN2014MN00697A (en)
PH12014502623A1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
MX342119B (en) Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators.
IN2013DN02555A (en)
MX342459B (en) Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators.
IN2015DN02109A (en)
IN2014DN03010A (en)